» Articles » PMID: 38287384

Exosomes: Potential Targets for the Diagnosis and Treatment of Neuropsychiatric Disorders

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2024 Jan 30
PMID 38287384
Authors
Affiliations
Soon will be listed here.
Abstract

The field of neuropsychiatry is considered a middle ground between neurological and psychiatric disorders, thereby bridging the conventional boundaries between matter and mind, consciousness, and function. Neuropsychiatry aims to evaluate and treat cognitive, behavioral, and emotional disorders in individuals with neurological conditions. However, the pathophysiology of these disorders is not yet fully understood, and objective biological indicators for these conditions are currently lacking. Treatment options are also limited due to the blood-brain barrier, which results in poor treatment effects. Additionally, many drugs, particularly antipsychotic drugs, have adverse reactions, which make them difficult to tolerate for patients. As a result, patients often abandon treatment owing to these adverse reactions. Since the discovery of exosomes in 1983, they have been extensively studied in various diseases owing to their potential as nanocellulators for information exchange between cells. Because exosomes can freely travel between the center and periphery, brain-derived exosomes can reflect the state of the brain, which has considerable advantages in diagnosis and treatment. In addition, administration of engineered exosomes can improve therapeutic efficacy, allow lesion targeting, ensure drug stability, and prevent systemic adverse effects. Therefore, this article reviews the source and biological function of exosomes, relationship between exosomes and the blood-brain barrier, relationship between exosomes and the pathological mechanism of neuropsychiatric disorders, exosomes in the diagnosis and treatment of neuropsychiatric disorders, and application of engineered exosomes in neuropsychiatric disorders.

Citing Articles

Circular RNAs: novel noncoding players in male infertility.

Babakhanzadeh E, Hoseininasab F, Khodadadian A, Nazari M, Hajati R, Ghafouri-Fard S Hereditas. 2024; 161(1):46.

PMID: 39551760 PMC: 11572108. DOI: 10.1186/s41065-024-00346-8.


Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W MedComm (2020). 2024; 5(8):e660.

PMID: 39015555 PMC: 11247338. DOI: 10.1002/mco2.660.


Dual-Omics Approach Unveils Novel Perspective on the Quality Control of Genetically Engineered Exosomes.

Olson C, Ivanov K, Boyes D, Bengford D, Ku J, Flojo R Pharmaceutics. 2024; 16(6).

PMID: 38931944 PMC: 11207238. DOI: 10.3390/pharmaceutics16060824.


Multiomics analysis of platelet-rich plasma promoting biological performance of mesenchymal stem cells.

Dai P, Wu Y, Gao Y, Li M, Zhu M, Xu H BMC Genomics. 2024; 25(1):564.

PMID: 38840037 PMC: 11151483. DOI: 10.1186/s12864-024-10329-8.

References
1.
Liu J, Clough S, Hutchinson A, Adamah-Biassi E, Popovska-Gorevski M, Dubocovich M . MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2015; 56:361-83. PMC: 5091650. DOI: 10.1146/annurev-pharmtox-010814-124742. View

2.
Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J . Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019; 15(8):1071-1080. DOI: 10.1016/j.jalz.2019.05.002. View

3.
Kuwano N, Kato T, Mitsuhashi M, Sato-Kasai M, Shimokawa N, Hayakawa K . Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study. J Affect Disord. 2018; 240:88-98. DOI: 10.1016/j.jad.2018.07.040. View

4.
Goetzl E, Abner E, Jicha G, Kapogiannis D, Schwartz J . Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB J. 2017; 32(2):888-893. PMC: 5888398. DOI: 10.1096/fj.201700731R. View

5.
Hu Y, Zhao M, Wang H, Guo Y, Cheng X, Zhao T . Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression. J Nanobiotechnology. 2023; 21(1):261. PMC: 10408189. DOI: 10.1186/s12951-023-02005-y. View